Baron & Budd Warns Patients of Potentially Misleading Xarelto and Pradaxa Ads
Dallas (Sept. 21, 2015) — The national law firm Baron & Budd is warning patients taking blood thinners about potentially misleading Xarelto and Pradaxa marketing material that may minimize the two blood thinner’s associated health risks.
Pradaxa was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the prevention of strokes and blood clots in patients suffering from atrial fibrillation. Xarelto was approved by the FDA soon after in 2011 to both help treat and prevent blood clots in patients. However, the two blood thinners may carry associated risks including uncontrolled internal bleeding. In addition, at this time there is no known antidote for either blood thinner to help stop bleeding, potentially causing some patients additional, severe health complications. The FDA has warned patients of the risk for bleeding in the past.
Despite both the associated risks and the lack of an available antidote for either Xarelto or Pradaxa, Baron & Budd believes that some prospective patients might be swayed by the two blood thinners’ marketing materials including online material for Pradaxa that may highlight the drug’s supposed benefits including “no regular blood tests” and “no dietary restrictions” — marketing that may both exaggerate the drug’s supposed benefits as well as downplay the drug’s serious risk for bleeding.
Both Pradaxa and Xarelto are part of a new generation of blood thinners that may be a welcome relief to patients who have long relied on Warfarin, a blood thinner that may involve serious changes to diet and lifestyle in part due to the Warfarin’s need to limit the development of Vitamin K in the body.
“We believe that the manufacturers of Xarelto and Pradaxa crossed a line when they promoted their respective drugs as being more convenient and safer than their predecessor Warfarin. Patients that take blood thinners rely on the drug’s efficacy for their very lives and we are concerned that the necessary, thorough studies to back up these marketing claims have not been performed in full,” says Russell Budd president and managing shareholder of the national law firm of Baron & Budd. “Patients deserve to know the difference between scientific fact and marketing when it comes to pharmaceuticals, especially when it comes to blood thinners.”
A Baron & Budd Xarelto and Pradaxa lawyer can help you if you suffered from severe, uncontrolled bleeding or other complications related to blood thinners. Contact us at 866-700-8994 or contact us online to learn more.
About Baron & Budd, P.C.
Baron & Budd, P.C. is a nationally recognized law firm with offices in Dallas, Austin, Baron Rouge and Los Angeles with a decades-long history of “Protecting What’s Right.” The firm represents both government and business entities as well as individuals in areas as complex as environmental contamination, the Gulf oil spill and financial fraud. In addition, the firm is one of the top law firms in the country on the front lines of dangerous pharmaceutical and medical device litigation. Baron & Budd’s large size and resources allow the firm to take on intricate and demanding cases that help lead the way in several areas of litigation, from pharmaceuticals to overtime pay violations.